舶望制药 is an RNAi drug R&D platform that focuses on developing siRNA therapeutics. The company says it will rely on a world-leading drug design and development platform to provide better treatments to patients globally. 舶望制药 recently completed a RMB 300 million A+ financing round. The round was led by Guotou Zhaoshang, with Huagai Capital, Yuanxi Haihe Fund and existing shareholder Sanyi Innovation Investment participating. Proceeds will be used to advance the global development of four clinical pipelines and to discover multiple preclinical candidate (PCC) molecules. The company will also use funds to iterate and upgrade its modification technology platform and extrahepatic delivery technology platform, and to strengthen its professional team.

Total raised

$41M

Funding rounds

1

Latest round

Series A

Latest activity

Nov 2023